Insulet reports on hybrid closed-loop Omnipod system
Insulet touted data this week from a clinical trial of its Omnipod Insulin Management System at the American Diabetes Association 79th Scientific Sessions in San Francisco. The company reported that the device is safe for use in children as young as two years old with Type 1 diabetes.
The study showed that the Acton, Mass.-based company’s Omnipod Horizon System was safe for up to four days of use in children who were as young as two years old with Type 1 diabetes. The study was done in a supervised hotel setting in free-living conditions. Participants were between two and six years old and had unrestricted meals and daily exercise. They had seven days of usual therapy at home with continuous glucose monitoring before participating in the supervised hotel setting study.
Participants in the study spent less time in hyperglycemia and spent significantly more time in the target glucose range, according to the study. They had better overnight glycemic control when compared to their regular therapy at home. Glucose control was maintained in the target range for 73% of the time overall and 85% of the time during an overnight period. Time spent in the hypoglycemic range was 2.9% overall and 2.0% overnight, according to Insulet.
“Critical for the pediatric population is the ability for caregivers, or kids, to customize insulin delivery to maintain optimal glycemic control, especially during exercise and following high-fat meals or periods after increased activity,” Dr. Jennifer L. Sherr of Yale University School of Medicine, said in a press release. “These data show that Insulet’s Omnipod Horizon System is able to meet that need in our youngest patients. This is critical, as children aged two- to six-years face unique diabetes management challenges and they are frequently understudied.”
The Omnipod Horizon Automated Insulin Delivery System is a hybrid closed-loop system that is designed to use estimated glucose values from a CGM to predict future blood glucose and adjust the insulin delivery as needed.
